Our Services
Medical Information
Helpful Resources
Published on: 9/12/2026
Older women often do experience more metoprolol side effects than younger people, because women metabolize the drug more slowly through CYP2D6 and can reach blood levels up to twice as high at the same dose, while age-related declines in liver and kidney function, lower body weight, blunted blood pressure reflexes, and polypharmacy further amplify effects like fatigue, dizziness, slow heart rate, low blood pressure, cold hands and feet, mood changes, and falls. Risk varies by dose, formulation, other medications, and conditions such as diabetes or thyroid disease, so several important factors need to be considered before assuming symptoms are unavoidable or that a dose change is safe. See below for the complete answer, including which symptoms warrant urgent attention and why stopping metoprolol abruptly can be dangerous.
If you are noticing new tiredness, lightheadedness, breathlessness, or a heart rate that feels unusually slow, it helps to sort out whether the medication, your dose, or something else entirely is driving it before your next appointment. A free, instant, online symptom check asks the same kinds of questions a clinician would, then explains which possible causes fit your pattern and how urgently you should be seen, so you can arrive prepared and get answers faster.
Last reviewed for medical accuracy: 09/12/2026
Metoprolol is a commonly prescribed beta-blocker used to manage high blood pressure, chest pain (angina), certain types of arrhythmias and to improve survival after a heart attack. As with any medication, individual responses and side effects can vary. Research and prescribing information suggest that age and sex both influence how people process metoprolol and how likely they are to experience side effects. Below, we explore why older women may be more susceptible to certain adverse effects than younger patients.
• Mechanism of action
• Blocks β₁-adrenergic receptors in the heart, slowing heart rate and reducing workload
• Lowers blood pressure by reducing cardiac output
• Metabolism and clearance
• Primarily broken down by the liver enzyme CYP2D6
• Eliminated through urine; kidney function plays a minor role
• Influencing factors
• Age-related liver and kidney changes
• Body composition (fat vs. muscle ratio)
• Genetic differences in CYP2D6 activity
• Sex-specific hormone and metabolic profiles
As we age, our bodies process drugs differently:
• Reduced liver blood flow and enzyme activity
– Can slow metoprolol breakdown, raising blood concentrations
– May prolong drug action and increase risk of dose-related side effects
• Decreased kidney function
– Mild impact on metoprolol elimination but important if combined with other kidney-cleared drugs
• Altered body composition
– Higher fat percentage can change drug distribution
– Lean body mass decreases, affecting volume of distribution
• Increased sensitivity
– Older adults often show greater pharmacodynamic response (stronger blood-pressure drop, slower heart rate)
These changes can lead older adults—especially those over 65—to experience more intense or prolonged effects from standard metoprolol doses.
Men and women can differ in how they absorb, distribute, metabolize and respond to medications:
• Body weight and composition
– On average, women have a higher body-fat percentage and lower lean mass than men
– May result in higher plasma concentrations of metoprolol per milligram dose
• Hormonal influences
– Estrogen can affect liver enzyme levels, including CYP2D6 activity
– Menopause and fluctuating hormone levels may alter drug clearance over time
• Genetic variability
– Some studies suggest women more often carry certain CYP2D6 variants that slow metabolism
Together, these factors can lead women—particularly older women—to clear metoprolol more slowly and maintain higher blood levels, heightening both intended and unintended effects.
All patients taking metoprolol should be aware of common and serious side effects. Older women may report some of these more often or with greater intensity:
Common side effects
• Fatigue or feeling unusually tired
• Dizziness, especially on standing (orthostatic hypotension)
• Bradycardia (heart rate below 60 beats per minute)
• Cold hands or feet
• Gastrointestinal symptoms (nausea, diarrhea)
Less common but important
• Depression or mood changes
• Sleep disturbances (insomnia or vivid dreams)
• Shortness of breath or wheezing (especially with asthma or COPD)
• Sexual dysfunction
Serious side effects (seek medical attention)
• Signs of very low heart rate (lightheadedness, fainting)
• Severe dizziness or sudden weakness
• Chest pain or worsening angina
• Signs of heart failure (rapid weight gain, ankle swelling, increasing breathlessness)
While large randomized trials of metoprolol did not always stratify results by both age and sex, several clinical observations and subgroup analyses suggest:
• Higher plasma levels in older women
– Pharmacokinetic studies report up to 20–30% higher blood concentrations in women vs. men at the same dose
– Clearance falls by an additional 20–40% in those over 65
• Increased reports of dizziness and fatigue
– Older women often cite “lightheadedness on standing” more frequently than younger cohorts
– May limit daily activities, increase fall risk
• Greater sensitivity to bradycardia
– More likely to require dose adjustments or temporary pauses
• Polypharmacy and comorbidities
– Older patients frequently take multiple medications
– Drug–drug interactions (e.g., other blood-pressure drugs, certain antidepressants) can amplify effects
These findings underscore the importance of individualized dosing, careful monitoring and regular review of all medications in older women on metoprolol.
Older women can often stay on metoprolol safely by following these guidelines:
• Start low and go slow
– Begin with the lowest effective dose (e.g., metoprolol 12.5–25 mg once daily)
– Increase gradually, monitoring blood pressure and heart rate
• Monitor vital signs
– Check heart rate and blood pressure at home, especially when changing dose
– Note any episodes of dizziness or fainting
• Review other medications
– Look for drugs that also lower blood pressure or heart rate
– Discuss potential interactions with your doctor or pharmacist
• Stay hydrated and stand up slowly
– Reduces risk of orthostatic hypotension
– Small meals and regular hydration help maintain stable blood volume
• Report mood or sleep changes
– Early discussion of depression, insomnia or vivid dreams allows timely adjustments
If you experience any worrying symptoms, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide whether you need urgent care or can discuss findings with your regular doctor. Always contact a healthcare professional if you notice:
• Persistent chest pain or pressure
• Fainting spells or severe dizziness
• Fast or unrelenting shortness of breath
• Any sudden, severe symptoms
• Older women often process metoprolol more slowly than younger people, resulting in higher blood levels.
• Age- and sex-related changes may increase the risk of side effects such as dizziness, fatigue and bradycardia.
• Close monitoring, starting with a low dose, and reviewing all medications can reduce risks.
• Open communication with your healthcare provider is vital—never hesitate to report new or worsening symptoms.
Always speak to a doctor about any possible life-threatening or serious concerns related to your medication or health. Your provider can adjust your dose, suggest alternative therapies or recommend additional monitoring to keep you safe and well.
(References)
* Botting JH, Gibson A. Beta-blocker withdrawal syndrome. Lancet. 1979 Apr 21;1(8121):875-6. PMID: 86121.
* Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362(9377):7-13. doi: 10.1016/S0140-6736(03)13800-7. PMID: 12853193.
* Nguyen DL, Wittich CM. Metoprolol-induced lichenoid dermatitis. J Gen Intern Med. 2011 Nov;26(11):1379-80. doi: 10.1007/s11606-011-1742-5. Epub 2011 May 26. PMID: 21614631; PMCID: PMC3208471.
* Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, Cooper JAD, Criner GJ, Curtis JL, Han MK, Hatipoğlu U, Helgeson ES, Jain VV, Kalhan R, Kaminsky D, Kaner R, Kunisaki KM, Lambert AA, Lammi MR, Lindberg S, Make BJ, Martinez FJ, McEvoy C, Panos RJ, Reed RM, Scanlon PD, Sciurba FC, Smith A, Sriram PS, Stringer WW, Weingarten JA, Wells JM, Westfall E, Lazarus SC, Connett JE, BLOCK COPD Trial Group. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med. 2019 Dec 12;381(24):2304-2314. doi: 10.1056/NEJMoa1908142. Epub 2019 Oct 20. PMID: 31633896; PMCID: PMC7416529.
* Glick A, Sista V, Johnson C. Oral Manifestations of Commonly Prescribed Drugs. Am Fam Physician. 2020 Nov 15;102(10):613-621. PMID: 33179891.
* Esmaeeli A, Keshavarz Z, Dehdar F, Assadi M, Seyedabadi M. The effects of carvedilol, metoprolol and propranolol on cisplatin-induced kidney injury. Drug Chem Toxicol. 2022 Jul;45(4):1558-1564. doi: 10.1080/01480545.2020.1846551. Epub 2020 Nov 16. PMID: 33198524.
* Nicol M, Sadoune M, Polidano E, Launay JM, Samuel JL, Azibani F, Cohen-Solal A. Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol. ESC Heart Fail. 2021 Apr;8(2):928-937. doi: 10.1002/ehf2.13198. Epub 2021 Feb 2. PMID: 33529501; PMCID: PMC8006653.
* Zamir A, Hussain I, Ur Rehman A, Ashraf W, Imran I, Saeed H, Majeed A, Alqahtani F, Rasool MF. Clinical Pharmacokinetics of Metoprolol: A Systematic Review. Clin Pharmacokinet. 2022 Aug;61(8):1095-1114. doi: 10.1007/s40262-022-01145-y. Epub 2022 Jun 28. PMID: 35764772.
* Niforatos JD, Ehmann MR, Balhara KS, Hinson JS, Ramcharran L, Lobner K, Weygandt PL. Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review. Acad Emerg Med. 2023 Feb;30(2):124-132. doi: 10.1111/acem.14618. Epub 2022 Dec 5. PMID: 36326565.
* Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, MAPLE-HCM Investigators. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11;393(10):949-960. doi: 10.1056/NEJMoa2504654. Epub 2025 Aug 30. PMID: 40888697.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.